The use of biological disease-modifying antirheumatic drugs and Janus kinase inhibitors in rheumatoid arthritis during the COVID-19 coronavirus disease pandemic: data from a telephone survey of 254 patients

The use of biological disease-modifying antirheumatic drugs and Janus kinase inhibitors in rheumatoid arthritis during the COVID-19 coronavirus disease pandemic: data from a telephone survey of 254 patients

The prescribing of biological disease-modifying antirheumatic drugs (bDMARDs) and Janus kinase inhibitors (iJAK) during the COVID-19 pandemic requires a balanced approach and tight monitoring of the patients.The aim of the study was to study the effect of bDMARDs and iJAK inhibitors on the condition...

Full description

Bibliographic Details
Main Authors: A. E. Karateev, E. Yu. Polishchuk, A. S. Potapova, E. V. Matyanova, A. S. Semashko, А. O. Bobkova, E. S. Filatova, V. N. Amirjanova, S. I. Glukhova, E. G. Zotkin, A. M. Lila
Format: Article
Language:Russian
Published: IMA PRESS LLC 2022-05-01
Series:Научно-практическая ревматология
Subjects:
rheumatoid arthritis
biological disease-modifying antirheumatic drugs
jak inhibitors
covid-19
Online Access:https://rsp.mediar-press.net/rsp/article/view/3146

Internet

https://rsp.mediar-press.net/rsp/article/view/3146

Similar Items